TY - JOUR
T1 - Biphasic effect of D-2 agonist quinpirole on locomotion and movements
AU - Eilam, David
AU - Szechtman, Henry
N1 - Funding Information:
This study was supported by funds from the Medical Research Council of Canada (MA8905). H.S. is a Research Associate of the Ontario Mental Health Foundation. Lilly Research Laboratories provided a generous gift of quinpirole hydrochloride.
PY - 1989/2/28
Y1 - 1989/2/28
N2 - The effects of the D-2 agonist quinpirole on forward progression, and on vertical and lateral movements, were measured for 2 h in rats injected with either saline, 0.03, 0.125, 0.5 or 8 mg/kg of the drug. Results showed that the drug had a biphasic effect: the lowest dose decreased and the high doses increased the amount of locomotion and of movement. The decrease in activity produced by the low dose had its onset within minutes after administration of the drug; persistent and marked hyperactivity was observed from about 60-80 min after injection of 0.5-8 mg/kg of quinpirole. Moreover, in animals injected with intermediate doses, the excitation was preceded by a brief period of reduced locomotion. It is suggested that the biphasic effect may reflect two independent actions of the drug, possibly on activity in the nucleus accumbens.
AB - The effects of the D-2 agonist quinpirole on forward progression, and on vertical and lateral movements, were measured for 2 h in rats injected with either saline, 0.03, 0.125, 0.5 or 8 mg/kg of the drug. Results showed that the drug had a biphasic effect: the lowest dose decreased and the high doses increased the amount of locomotion and of movement. The decrease in activity produced by the low dose had its onset within minutes after administration of the drug; persistent and marked hyperactivity was observed from about 60-80 min after injection of 0.5-8 mg/kg of quinpirole. Moreover, in animals injected with intermediate doses, the excitation was preceded by a brief period of reduced locomotion. It is suggested that the biphasic effect may reflect two independent actions of the drug, possibly on activity in the nucleus accumbens.
KW - (Forward progression, Movement, Rat)
KW - Dopamine
KW - Hyperactivity
KW - Hypoactivity
UR - http://www.scopus.com/inward/record.url?scp=0024518016&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(89)90837-6
DO - 10.1016/0014-2999(89)90837-6
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0024518016
SN - 0014-2999
VL - 161
SP - 151
EP - 157
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 2-3
ER -